PVP-Guided Decongestive Therapy in HF

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marmara University
• Collaborators: Basaksehir Cam & Sakura Şehir Hospital; Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
• Treatments: Diuretics

Criteria

Inclusion criteria

• Hospitalization for heart failure (de novo or decompensated chronic heart failure)

• Age >18

Exclusion criteria

• A prior history of upper extremity venous disease

• Serum creatinine ≥ 3.5 mg/dL

• Severe stenotic valvular disease

• Hypertrophic obstructive cardiomyopathy

Exclusion from long term follow-up after randomization

• Unable to obtain first and pre-discharge PVP due to technical issues (unable to access an upper extremity vein, negative augmentation test)

• In-hospital intubation

• Need for high-dose vasopressor or inotrope medications (≥10 mcg.kg.-1.min-1 dopamine, dobutamine or equivalent)

• Need for intra-aortic balloon pump support

• In-hospital need for dialysis or veno-venous ultrafiltration